Startseite Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis

  • Jessica Zuin , Gianluca Veggiani , Paolo Pengo , Andrea Gallotta , Alessandra Biasiolo , Natascia Tono , Angelo Gatta , Patrizia Pontisso , Radovan Toth , Dean Cerin , Vladimir Frecer , Sabrina Meo , Massimo Gion , Giorgio Fassina und Luca Beneduce
Veröffentlicht/Copyright: 10. Dezember 2009
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) is a useful biomarker for the risk of development of hepatocellular carcinoma (HCC) in patients with cirrhosis due to its progressive increase associated to HCC evolution. In patients with cirrhosis, other assays have been affected by interfering reactivities of IgM. In this study, the analytical specificity of the SCCA-IgM assay was assessed by evaluating SCCA-IgM measurement dependence on different capture phases, and by measuring the recovery of SCCA-IgM reactivity following serum fractionation.

Methods: Serum samples from 82 patients with cirrhosis were analyzed. SCCA-IgM was measured using the reference test (Hepa-IC, Xeptagen, Italy) that is based on rabbit oligoclonal anti-squamous cell carcinoma antigen (SCCA) and a dedicated ELISA with a mouse monoclonal anti-SCCA as the capture antibody.

Results: SCCA-IgM concentrations measured with the reference assay (median value=87 AU/mL) were higher than those measured with the mouse monoclonal test (median value=78 AU/mL). However, the differences in the SCCA-IgM distribution were not statistically significant (p>0.05). When SCCA-IgM concentrations measured with both tests were compared, a linear correlation was found (r=0.77, p<0.05). Fractionation of the most reactive sera by gel-filtration chromatography showed that total recovery of SCCA-IgM reactivity was seen only in the fractions corresponding to components with a molecular weight higher than IgM and SCCA (>2000 kDa) with both tests.

Conclusions: The equivalence of both SCCA-IgM assays and the absence of reactivity not related to immune complexes support the analytical specificity of SCCA-IgM measurements. The results validate the assessment of SCCA-IgM for prognostic purposes in patients with cirrhosis.

Clin Chem Lab Med 2010;48:217–23.


Corresponding author: Luca Beneduce, PhD, XEPTAGEN S.p.A., Via delle Industrie 9, 30175 Marghera Venice, Italy Phone: +39 041 5093910, Fax: +39 041 5093884,

Received: 2009-9-22
Accepted: 2009-10-11
Published Online: 2009-12-10
Published in Print: 2010-02-01

©2010 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Review
  2. Elevated serum γ-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer – a narrative review
  3. Minireview
  4. Artificial intelligence for diagnostic purposes: principles, procedures and limitations
  5. General Clinical Chemistry and Laboratory Medicine
  6. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005–2006
  7. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults
  8. Plasma osteopontin concentrations in preeclampsia – is there an association with endothelial injury?
  9. Determination of globotriaosylceramide in plasma and urine by mass spectrometry
  10. Effect of inflammation induced by prolonged exercise on circulating erythroid progenitors and markers of erythropoiesis
  11. The Beckman DxI 800 prolactin assay demonstrates superior specificity for monomeric prolactin
  12. Stability of cerebrospinal fluid/serum glucose ratio and cerebrospinal fluid lactate concentrations over 24 h: analysis of repeated measurements
  13. O-β-N-acetyl-D-glucosaminidase in erythrocytes of Italian air force acrobatic pilots
  14. Validation and Outcome Studies
  15. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis
  16. Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
  17. Reference Values and Biological Variations
  18. Applicability of common reference intervals for serum creatinine concentrations to the Croatian population
  19. Laboratory reference intervals during pregnancy, delivery and the early postpartum period
  20. Determination of serum holotranscobalamin concentrations with the AxSYM active B12 assay: cut-off point evaluation in the clinical laboratory
  21. Definition of reference ranges for the platelet distribution width (PDW): a local need
  22. Cancer Diagnostics
  23. Mean leukocyte telomere length and risk of incident colorectal carcinoma in women: a prospective, nested case-control study
  24. Heat shock protein 27 is over-expressed in tumor tissues and increased in sera of patients with gastric adenocarcinoma
  25. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
  26. A novel sensitive immunoassay by nucleic acid barcode dot and its application in the detection of prostate-specific antigen
  27. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays
  28. Infectious Diseases
  29. Use of flow cytometry (Sysmex® UF-100) to screen for positive urine cultures: in search for the ideal cut-off
  30. Letters to the Editor
  31. Improving laboratory efficiencies through significant time reduction in the preanalytical phase
  32. Comparison of the Vitek 2 system with the CLSI broth microdilution, disk diffusion, and sterol quantitation methods for determining fluconazole susceptibility against Candida spp.
Heruntergeladen am 14.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2010.044/html
Button zum nach oben scrollen